OBJECTIVE: Schizophrenia is a heterogeneous neurodevelopmental disorder. Patients with high levels of negative symptoms have been identified as a specific subtype, but little is known about how the neurodevelopmental course may differ in this group. This study aimed to characterize developmental trajectories of premorbid social withdrawal and cognitive decline between patients with high versus low levels of negative symptoms in youth with schizophrenia-spectrum disorders. METHOD: A standardized timeline was used to delineate the emergence of psychosis, social withdrawal, and cognitive decline in 52 subjects aged 8 to 19 with schizophrenia (n=36), schizophreniform (n=6), or schizoaffective disorder (n=10). The sample was divided into subgroups of high- (n=26) versus low- (n=26) negative symptoms, and developmental trajectories of premorbid symptoms were compared between groups. RESULTS: Mean ages for emergence of social withdrawal, cognitive decline, and psychosis were 11.1 years (SD=2.5), 11.9 (SD=4.4) and 13.2 years (SD=1.2), respectively. In the high-negative symptom group, the premorbid developmental trajectory for social withdrawal was more protracted. This group also had more severe cognitive decline at the onset of psychosis, but the premorbid trajectories for cognitive decline did not differ significantly between groups. CONCLUSIONS: This work documents a more severe and protracted trajectory of premorbid social withdrawal in patients with high levels of negative symptoms in comparison to those with low-negative symptoms. The findings reported here are supportive of the hypothesis that patients with illness characterized by high levels of negative symptoms may represent a subgroup with distinct neurodevelopmental abnormalities.
OBJECTIVE:Schizophrenia is a heterogeneous neurodevelopmental disorder. Patients with high levels of negative symptoms have been identified as a specific subtype, but little is known about how the neurodevelopmental course may differ in this group. This study aimed to characterize developmental trajectories of premorbid social withdrawal and cognitive decline between patients with high versus low levels of negative symptoms in youth with schizophrenia-spectrum disorders. METHOD: A standardized timeline was used to delineate the emergence of psychosis, social withdrawal, and cognitive decline in 52 subjects aged 8 to 19 with schizophrenia (n=36), schizophreniform (n=6), or schizoaffective disorder (n=10). The sample was divided into subgroups of high- (n=26) versus low- (n=26) negative symptoms, and developmental trajectories of premorbid symptoms were compared between groups. RESULTS: Mean ages for emergence of social withdrawal, cognitive decline, and psychosis were 11.1 years (SD=2.5), 11.9 (SD=4.4) and 13.2 years (SD=1.2), respectively. In the high-negative symptom group, the premorbid developmental trajectory for social withdrawal was more protracted. This group also had more severe cognitive decline at the onset of psychosis, but the premorbid trajectories for cognitive decline did not differ significantly between groups. CONCLUSIONS: This work documents a more severe and protracted trajectory of premorbid social withdrawal in patients with high levels of negative symptoms in comparison to those with low-negative symptoms. The findings reported here are supportive of the hypothesis that patients with illness characterized by high levels of negative symptoms may represent a subgroup with distinct neurodevelopmental abnormalities.
Authors: S M Lawrie; M Byrne; P Miller; A Hodges; R A Clafferty; D G Cunningham Owens; E C Johnstone Journal: Br J Psychiatry Date: 2001-06 Impact factor: 9.319
Authors: Thomas H McGlashan; Jean Addington; Tyrone Cannon; Markus Heinimaa; Patrick McGorry; Mary O'Brien; David Penn; Diana Perkins; Raimo K R Salokangas; Barbara Walsh; Scott W Woods; Alison Yung Journal: Schizophr Bull Date: 2007-05-04 Impact factor: 9.306
Authors: Scott W Woods; Alan Breier; Robert B Zipursky; Diana O Perkins; Jean Addington; Tandy J Miller; Keith A Hawkins; Eva Marquez; Stacy R Lindborg; Mauricio Tohen; Thomas H McGlashan Journal: Biol Psychiatry Date: 2003-08-15 Impact factor: 13.382
Authors: J Binder; M Albus; W Hubmann; J Scherer; N Sobizack; U Franz; F Mohr; S Hecht Journal: Eur Arch Psychiatry Clin Neurosci Date: 1998 Impact factor: 5.270
Authors: Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer Journal: Schizophr Res Date: 2019-01-31 Impact factor: 4.939
Authors: Ian B Hickie; Daniel F Hermens; Sharon L Naismith; Adam J Guastella; Nick Glozier; Jan Scott; Elizabeth M Scott Journal: BMC Psychiatry Date: 2013-11-12 Impact factor: 3.630